JP2019510739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510739A5 JP2019510739A5 JP2018540415A JP2018540415A JP2019510739A5 JP 2019510739 A5 JP2019510739 A5 JP 2019510739A5 JP 2018540415 A JP2018540415 A JP 2018540415A JP 2018540415 A JP2018540415 A JP 2018540415A JP 2019510739 A5 JP2019510739 A5 JP 2019510739A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition according
- mammal
- gfral
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/074809 WO2017147742A1 (en) | 2016-02-29 | 2016-02-29 | Gfral receptor therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510739A JP2019510739A (ja) | 2019-04-18 |
| JP2019510739A5 true JP2019510739A5 (https=) | 2019-05-30 |
Family
ID=59742416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540415A Pending JP2019510739A (ja) | 2016-02-29 | 2016-02-29 | Ｇｆｒａｌ受容体療法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3423094A4 (https=) |
| JP (1) | JP2019510739A (https=) |
| CN (1) | CN108697795A (https=) |
| WO (1) | WO2017147742A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US20170299608A1 (en) * | 2016-03-04 | 2017-10-19 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| MY194669A (en) | 2016-03-31 | 2022-12-12 | Ngm Biopharmaceuticals Inc | Binding Proteins and Methods of use Thereof |
| KR20190059312A (ko) * | 2016-10-12 | 2019-05-30 | 얀센 바이오테크 인코포레이티드 | Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| EA202191105A1 (ru) * | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| EP4041281B1 (en) | 2019-10-04 | 2025-11-26 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| US12398211B2 (en) | 2020-06-04 | 2025-08-26 | Daegu Gyeongbuk Institute Of Science And Technology | GFRAL-antagonistic antibody and use thereof |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| US20240182585A1 (en) | 2021-03-31 | 2024-06-06 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| CN117693525A (zh) * | 2021-06-30 | 2024-03-12 | 上海津曼特生物科技有限公司 | 抗gfral抗体及其应用 |
| CN118580334A (zh) * | 2023-03-03 | 2024-09-03 | 北京志道生物科技有限公司 | 一种多肽分子 |
| IT202300006387A1 (it) * | 2023-03-31 | 2024-10-01 | Univ Degli Studi Roma La Sapienza | Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica |
| CN116444667B (zh) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2478369A1 (en) * | 2002-03-05 | 2003-09-18 | Genentech, Inc. | Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same |
| US20100278843A1 (en) * | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| EP2694092B1 (en) * | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| CN102321173B (zh) * | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| JO3462B1 (ar) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| ES2791183T3 (es) * | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
| WO2017121865A1 (en) * | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
-
2016
- 2016-02-29 CN CN201680082844.2A patent/CN108697795A/zh active Pending
- 2016-02-29 JP JP2018540415A patent/JP2019510739A/ja active Pending
- 2016-02-29 EP EP16891935.5A patent/EP3423094A4/en not_active Withdrawn
- 2016-02-29 WO PCT/CN2016/074809 patent/WO2017147742A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510739A5 (https=) | ||
| JP2020536109A5 (https=) | ||
| JP2012525128A5 (https=) | ||
| JP2016512213A5 (https=) | ||
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| JP2019506841A5 (https=) | ||
| JP2022513420A5 (https=) | ||
| JP2018515088A5 (https=) | ||
| RU2015127780A (ru) | Агонисты рецепторов глюкагона/glp-1 для лечения ожирения | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP2016539096A5 (https=) | ||
| JP2016534052A5 (https=) | ||
| JP2017113019A5 (https=) | ||
| JP2014221758A5 (https=) | ||
| JP2017510567A5 (https=) | ||
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| JP2018535948A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| JP2016537340A5 (https=) | ||
| JP2017522903A5 (https=) | ||
| JP2016020389A5 (https=) | ||
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| JP2016519650A5 (https=) | ||
| JP2015522252A5 (https=) | ||
| JP2023065390A (ja) | 治療用抗ｃｄ４０リガンド抗体 |